Table 3.
RGD effects on glioma cell apoptosis as assessed by a quantitative in vitro morphologic assay on adherent cells (Experiment 1) or by a 7AAD assay where nonadherent and adherent cells were analyzed (Experiment 2).
| Tumor |
10-08-MG |
04-11-MG |
13-06-MG |
14-07-MG |
|
|---|---|---|---|---|---|
| Additive to Medium | Incubation time (hr) | Apoptotic % | Apoptotic % | Apoptotic % | Apoptotic % |
| none | 4 | 1.1 | 1.6 | 2.8 | 3.6 |
| 18 | 7.5 | 0.8 | 3.3 | 0.4 | |
| Scrambled | 4 | 4.7 | 0.8 | 4.9 | 8.3 |
| 18 | 13.6 | 0.6 | 4.8 | 12.0 | |
| RGD peptide | 4 | 8.4 | 2.1 | 4.2 | 15.8 |
| 18 | 18.7 | 3.0 | 7.2 | 17.8 |
** Glioma cells were plated into 6 well plates for 24 hr. RGD peptide or scrambled peptide (0.001 M), or fresh culture medium were then added to the wells. Coincubation for 4 or 18 hr at 37°C in a humidified 5% CO2 chamber was followed by collection of the adherent and nonadherent cells. Cells were incubated with 7AAD (20 μg/ml in PBS) for 20 min at 4 °C, rinsed once and resuspended in 400 μlof PBS. Samples were analyzed by flow cytometry. The percentages of glioma cells within the segregated live, apoptotic, and late apoptotic/necrotic populations were determined.